{
    "ticker": "LASR",
    "name": "NantKwest, Inc.",
    "description": "NantKwest, Inc. is a clinical-stage immunotherapy company focused on developing and commercializing innovative cell-based therapies for cancer and infectious diseases. Founded in 2015, NantKwest aims to harness the power of the immune system to treat various malignancies and chronic infections. The company\u2019s proprietary technology platform is designed to manufacture off-the-shelf, allogeneic immune cell therapies, including natural killer (NK) cell therapies and other immune effector cells. NantKwest\u2019s lead product candidate, NK cell therapy, has demonstrated promising results in early clinical trials, showing the potential to improve patient outcomes in various tumor types. The company is committed to advancing its clinical pipeline through rigorous research and development, with an emphasis on personalized medicine. NantKwest\u2019s mission is to transform the treatment of cancer and infectious diseases by providing effective, safe, and accessible therapies that enhance the body's immune response. As the field of immunotherapy continues to evolve, NantKwest is at the forefront of this revolution, seeking to bring breakthrough treatments to patients in need.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Culver City, California, USA",
    "founded": "2015",
    "website": "https://www.nantkwest.com",
    "ceo": "Dr. Patrick Soon-Shiong",
    "social_media": {
        "twitter": "https://twitter.com/NantKwest",
        "linkedin": "https://www.linkedin.com/company/nantkwest/"
    },
    "investor_relations": "https://investors.nantkwest.com",
    "key_executives": [
        {
            "name": "Dr. Patrick Soon-Shiong",
            "position": "CEO"
        },
        {
            "name": "Dr. Richard K. Korf",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy",
            "products": [
                "NK Cell Therapy",
                "CAR NK Cells"
            ]
        }
    ],
    "seo": {
        "meta_title": "NantKwest, Inc. | Innovative Immunotherapy Solutions",
        "meta_description": "Explore NantKwest, Inc., a leader in immunotherapy dedicated to developing advanced cell-based therapies for cancer and infectious diseases.",
        "keywords": [
            "NantKwest",
            "Immunotherapy",
            "Cancer Treatment",
            "Natural Killer Cells",
            "Cell Therapy"
        ]
    },
    "faq": [
        {
            "question": "What is NantKwest known for?",
            "answer": "NantKwest is known for its innovative cell-based immunotherapy solutions for cancer and infectious diseases."
        },
        {
            "question": "Who is the CEO of NantKwest?",
            "answer": "Dr. Patrick Soon-Shiong is the CEO of NantKwest, Inc."
        },
        {
            "question": "Where is NantKwest headquartered?",
            "answer": "NantKwest is headquartered in Culver City, California, USA."
        },
        {
            "question": "What are NantKwest's main products?",
            "answer": "NantKwest's main products include NK cell therapies and CAR NK cells."
        },
        {
            "question": "When was NantKwest founded?",
            "answer": "NantKwest was founded in 2015."
        }
    ],
    "competitors": [
        "NVTA",
        "CRSP",
        "EDIT",
        "ZGNX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "JNJ",
        "PFE"
    ]
}